Business Wire

Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
Business Wire

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
MD&M East

Reprieve Study Holds Promise for ADHF Care

Reprieve Cardiovascular today announced results for its first-in-human study of the Reprieve system for the treatment of acute decompensated heart failure (ADHF). The study focused on the device’s ...